A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Nadia Harbeck,S. Saupe,Elke Jäger,Marcus Schmidt,Rolf Kreienberg,Lothar Müller,Burkhard Otremba,Dirk Waldenmaier,Julia Dorn,Mathias Warm,Michael Scholz,Michael Untch,Maike de Wit,Jana Barinoff,Hans-Joachim Lück,Philipp Harter,D Augustin,Paul Harnett,Matthias W. Beckmann,Salah-Eddin Al-Batran

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

2010

Purpose The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC).

Keywords:

Capecitabine
Pegylated Liposomal Doxorubicin
Cancer research
Vinorelbine
Paclitaxel
Methotrexate
Oncology
Medicine
Metastatic breast cancer
Internal medicine
Chemotherapy
Cyclophosphamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations